The majority of pre-COVID-19 controls that tested positive within the groups had IgM against both S protein and RBD, 1.5% (n = 8/520 testing antibody-positive, Figure S5E) and 2.1% (n = 11/520 antibody-positive, Figure S5F), respectively. This evidence concerns the gene CD40LG and COVID-19.